Bessemer Group Inc. boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 0.7% during the second quarter, Holdings Channel reports. The firm owned 33,388 shares of the company’s stock after buying an additional 247 shares during the period. Bessemer Group Inc.’s holdings in Novo Nordisk A/S were worth $1,431,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of NVO. Renaissance Technologies LLC raised its stake in Novo Nordisk A/S by 17.7% in the first quarter. Renaissance Technologies LLC now owns 16,409,200 shares of the company’s stock valued at $562,507,000 after buying an additional 2,463,300 shares during the period. Bank of America Corp DE raised its stake in Novo Nordisk A/S by 3.2% in the first quarter. Bank of America Corp DE now owns 12,102,582 shares of the company’s stock valued at $414,876,000 after buying an additional 380,536 shares during the period. Fisher Asset Management LLC raised its stake in Novo Nordisk A/S by 12.9% in the second quarter. Fisher Asset Management LLC now owns 11,690,997 shares of the company’s stock valued at $501,427,000 after buying an additional 1,331,992 shares during the period. State Street Corp raised its stake in Novo Nordisk A/S by 64,406.4% in the first quarter. State Street Corp now owns 5,593,351 shares of the company’s stock valued at $191,740,000 after buying an additional 5,584,680 shares during the period. Finally, Sustainable Growth Advisers LP raised its stake in Novo Nordisk A/S by 17.3% in the first quarter. Sustainable Growth Advisers LP now owns 4,068,896 shares of the company’s stock valued at $139,482,000 after buying an additional 598,644 shares during the period. 6.40% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S (NYSE:NVO) opened at 45.81 on Friday. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $47.98. The company has a market capitalization of $113.62 billion, a price-to-earnings ratio of 18.74 and a beta of 0.63. The stock has a 50 day moving average of $42.76 and a 200 day moving average of $38.81.

The firm also recently announced an annual dividend, which will be paid on Tuesday, August 29th. Stockholders of record on Monday, August 21st will be paid a dividend of $0.336 per share. This represents a dividend yield of 1.07%. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date of this dividend is Friday, August 18th. Novo Nordisk A/S’s payout ratio is presently 36.00%.

COPYRIGHT VIOLATION WARNING: “Bessemer Group Inc. Has $1.43 Million Stake in Novo Nordisk A/S (NYSE:NVO)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/bessemer-group-inc-has-1-43-million-stake-in-novo-nordisk-as-nysenvo/1480659.html.

NVO has been the topic of several analyst reports. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, April 19th. BidaskClub lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Finally, TheStreet raised shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $53.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.